RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer - the S.U.R.G.U.V.A.N.T. trial.

BMC Cancer · 2018 · PMC6091184 · PMID 30081854

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

approached significancep = 0.07so close (0.05 < p ≤ 0.1)

The rate of TNF-α attenuation in Taurolidine treated patients compared to placebo over the 7 days approached significance ( p = 0.07).

also in 8,237 other papers

a significant trendno p-value reported

Although there was no difference seen at the early 24 h time-point, post hoc analysis demonstrated a significant trend for IL-6 attenuation over the 7 day post-operative period in Taurolidine versus the control group, with levels being significantly different at post-operative day 7.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.